Osteoporosis
Conference Coverage
Meta-analysis: Bisphosphonates mitigate glucocorticoid-induced bone loss
MADRID – The drugs examined were ibandronate, alendronate, risedronate, etidronate, and clodronate.
Conference Coverage
Romosozumab cuts new vertebral fracture risk by 73%, but safety data are concerning
MADRID – Investigational bone-building drug looks promising, but safety concerns emerge.
From the Journals
Updated osteoporosis guideline advocates bisphosphonates, nixes estrogens
Even though well-designed, randomized controlled trials amply demonstrate the effectiveness of bisphosphonates in preventing fractures,...
Conference Coverage
New evidence bisphosphonates may prevent OA
LAS VEGAS – A favorable signal is seen in the Osteoarthritis Initiative.
News
FDA approves abaloparatide for postmenopausal osteoporosis
The Food and Drug Administration has approved abaloparatide (Tymlos) for postmenopausal women with osteoporosis at high risk for fracture.
News from the FDA/CDC
Just the FRAX: National fracture risks estimated
A risk-estimating algorithm puts 10-year probability of major osteoporotic fracture at 5.3% in adults aged 40 years and over.
From the Journals
Study shows no adverse events with long-term denosumab in postmenopausal women
Denosumab, taken long term, is not linked with any adverse events, an analysis of the participants in the FREEDOM trial showed.
Feature
New guidance: Bone health is front and center in functional hypothalamic amenorrhea care
Diagnosing can be tricky, but several viable treatment options exist.
Conference Coverage
Large, intermittent vitamin D doses may increase fracture, fall risk in elderly
Does vitamin D, which builds strong bones, also have a paradoxical effect?
From the Journals
Targeting Paget’s bone symptoms supported in long-term trial
A continued lack of difference in benefits between intensive bisphosphonate treatment of Paget’s disease of bone versus symptomatic treatment in a...
From the Journals
Bone fractures more likely to occur in psoriasis, PsA patients
This is the first population-based study to examine the relationship between bone fractures and psoriasis, according to the authors.